ASH 2014: CAR-T cell therapies generate buzz
This article was originally published in Scrip
Executive Summary
Excitement around chimeric antigen receptor (CAR) T cell therapies has been building during the past year, because of the potential to essentially cure significant numbers of patients with hard to treat cancers, and the buzz came to a fever pitch during the American Society of Hematology (ASH) annual meeting in San Francisco from 6 to 9 December.